Cannara Biotech Inc (LOVE) - Net Assets
Based on the latest financial reports, Cannara Biotech Inc (LOVE) has net assets worth CA$111.21 Million CAD (≈ $80.45 Million USD) as of November 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$173.84 Million ≈ $125.76 Million USD) and total liabilities (CA$62.63 Million ≈ $45.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of Cannara Biotech Inc for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$111.21 Million |
| % of Total Assets | 63.97% |
| Annual Growth Rate | 31.86% |
| 5-Year Change | 59.43% |
| 10-Year Change | N/A |
| Growth Volatility | 81.9 |
Cannara Biotech Inc - Net Assets Trend (2018–2025)
This chart illustrates how Cannara Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore LOVE asset base for the complete picture of this company's asset base.
Annual Net Assets for Cannara Biotech Inc (2018–2025)
The table below shows the annual net assets of Cannara Biotech Inc from 2018 to 2025. For live valuation and market cap data, see Cannara Biotech Inc (LOVE) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | CA$102.22 Million ≈ $73.95 Million |
+16.22% |
| 2024-08-31 | CA$87.95 Million ≈ $63.62 Million |
+10.29% |
| 2023-08-31 | CA$79.74 Million ≈ $57.69 Million |
+19.49% |
| 2022-08-31 | CA$66.74 Million ≈ $48.28 Million |
+4.09% |
| 2021-08-31 | CA$64.12 Million ≈ $46.38 Million |
+67.12% |
| 2020-08-31 | CA$38.36 Million ≈ $27.75 Million |
-23.16% |
| 2019-08-31 | CA$49.93 Million ≈ $36.12 Million |
+238.67% |
| 2018-08-31 | CA$14.74 Million ≈ $10.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cannara Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 229117700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CA$178.28K | 0.17% |
| Other Components | CA$102.04 Million | 99.83% |
| Total Equity | CA$102.22 Million | 100.00% |
Cannara Biotech Inc Competitors by Market Cap
The table below lists competitors of Cannara Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Megaforce Co Ltd
TWO:3294
|
$126.86 Million |
|
Kyung Nong Corporation
KO:002100
|
$126.88 Million |
|
HYUNDAI FEED Inc
KQ:016790
|
$126.96 Million |
|
Aesler Grup Internasional Tbk Pt
JK:RONY
|
$127.08 Million |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
$126.79 Million |
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
$126.73 Million |
|
Paxman AB
ST:PAX
|
$126.73 Million |
|
Her Chee Industrial Co Ltd
TWO:8937
|
$126.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cannara Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 87,951,489 to 102,220,977, a change of 14,269,488 (16.2%).
- Net income of 13,076,193 contributed positively to equity growth.
- Other factors increased equity by 1,193,295.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$13.08 Million | +12.79% |
| Other Changes | CA$1.19 Million | +1.17% |
| Total Change | CA$- | 16.22% |
Book Value vs Market Value Analysis
This analysis compares Cannara Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 86.23x to 1.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-08-31 | CA$0.02 | CA$1.83 | x |
| 2019-08-31 | CA$0.07 | CA$1.83 | x |
| 2020-08-31 | CA$0.05 | CA$1.83 | x |
| 2021-08-31 | CA$0.07 | CA$1.83 | x |
| 2022-08-31 | CA$0.08 | CA$1.83 | x |
| 2023-08-31 | CA$0.88 | CA$1.83 | x |
| 2024-08-31 | CA$0.98 | CA$1.83 | x |
| 2025-08-31 | CA$1.12 | CA$1.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cannara Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.79%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.20%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.65x
- Recent ROE (12.79%) is above the historical average (-5.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -14.33% | -488.38% | 0.01x | 1.96x | CA$-3.59 Million |
| 2019 | -26.11% | -587.28% | 0.03x | 1.44x | CA$-17.03 Million |
| 2020 | -32.54% | -504.40% | 0.05x | 1.43x | CA$-16.32 Million |
| 2021 | -2.38% | -9.38% | 0.18x | 1.44x | CA$-7.94 Million |
| 2022 | 3.45% | 6.43% | 0.29x | 1.88x | CA$-4.37 Million |
| 2023 | 8.71% | 12.13% | 0.40x | 1.77x | CA$-1.03 Million |
| 2024 | 7.32% | 7.88% | 0.53x | 1.76x | CA$-2.36 Million |
| 2025 | 12.79% | 12.20% | 0.64x | 1.65x | CA$2.85 Million |
Industry Comparison
This section compares Cannara Biotech Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $739,937,582
- Average return on equity (ROE) among peers: -40.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cannara Biotech Inc (LOVE) | CA$111.21 Million | -14.33% | 0.56x | $126.80 Million |
| Aurora Cannabis Inc (ACB) | $601.87 Million | -11.52% | 0.39x | $193.63 Million |
| Amotiv Limited (AOV) | $915.11 Million | 1.59% | 0.43x | $553.67 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-4.29 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $841.07K | -309.08% | 1.52x | $13.17 Million |
| Avant Brands Inc (AVNT) | $-490.96K | 0.00% | 0.00x | $4.13 Million |
| Bausch Health Companies Inc (BHC) | $5.23 Billion | -16.55% | 4.34x | $2.06 Billion |
| CanadaBis Capital Inc (CANB) | $150.00K | 0.00% | 0.00x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $550.08 Million | -25.79% | 1.50x | $12.59 Million |
| Cipher Pharmaceuticals Inc (CPH) | $80.52 Million | 25.31% | 0.07x | $326.62 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $22.27 Million | -71.36% | 0.11x | $148.65 Million |
About Cannara Biotech Inc
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. I… Read more